Surrozen (SRZN) Income from Continuing Operations (2020 - 2026)
Surrozen (SRZN) posted quarterly Income from Continuing Operations of 32502000.0 for Q1 2026, down 126.42% year-over-year from 123039612.34 in Q1 2025, and down 259.1% quarter-over-quarter from 9051000.0 in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Surrozen's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 32502000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 126.42% year-over-year to 32502000.0; the TTM figure through Mar 2026 stood at 76586000.0 (up 10.05% YoY), while the FY2025 annual figure was 51934000.0, up 31.43% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 32502000.0, down from 9051000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 104000.0 in Q3 2024, with the low at 60101000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 14745000.0 (2023), against an average of 17493588.24.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 100.71% in 2024, then plunged 17616.35% in 2025.
- Surrozen's Income from Continuing Operations stood at 1698000.0 in 2022, then plunged by 443.05% to 9221000.0 in 2023, then tumbled by 551.78% to 60101000.0 in 2024, then surged by 84.94% to 9051000.0 in 2025, then plunged by 259.1% to 32502000.0 in 2026.
- Business Quant data shows SRZN's Income from Continuing Operations at 32502000.0 in Q1 2026, 9051000.0 in Q4 2025, and 18217000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Surrozen | 258.80 Mn | 258.80 Mn | - | -9.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.43 Mn |
| Mar 31, 2026 | -9.54 Mn |
| Dec 31, 2025 | -11.85 Mn |
| Sep 30, 2025 | -9.97 Mn |
| Jun 30, 2025 | -7.99 Mn |
| Mar 31, 2025 | -9.26 Mn |
| Dec 31, 2024 | -8.21 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | -8.56 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -9.22 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -9.65 Mn |
| Mar 31, 2023 | -14.05 Mn |
| Dec 31, 2022 | -1.70 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -14.01 Mn |
| Mar 31, 2022 | -14.44 Mn |
| Dec 31, 2021 | -14.95 Mn |
| Sep 30, 2021 | -13.69 Mn |